History
A list of downloadable documents created during development.
Background information
-
-
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
-
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix A provisional matrix of stakeholders
-
-
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix B proposal paper presented to the Institute's Guidance Executive
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): EIA form guidance development
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): EIA form guidance development
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): EIA form guidance development (PDF 75 KB)
Rheumatoid arthritis - tocilizumab (rapid review TA198): final appraisal determination
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final appraisal determination information
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final appraisal determination document
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): response to consultee, commentator and public comments on the Appraisal Consultation Document
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): consultee and commentator comments on the ACD
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from MSD
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from MSD (PDF 556 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Roche
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Roche (PDF 179 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from the British Society of Rheumatology
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from the Royal College of Nursing
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Abbott
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Abbott (PDF 127 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Pfizer
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Pfizer (PDF 225 KB)
Rheumatoid arthritis - tocilizumab (rapid review TA198): appraisal consultation
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): appraisal consultation
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): appraisal consultation document information
-
-
Rheumatoid arthritis - abatacept (2nd line): EIA form (guidance development)
-
Rheumatoid arthritis - abatacept (2nd line): EIA form (guidance development) (PDF 23 KB)
-
Rheumatoid arthritis - abatacept (2nd line): press release information
-
Download PDF version
-
2011/101 NICE appraisal on abatacept for rheumatoid arthritis (PDF 71 KB)
-
Rheumatoid arthritis - abatacept (2nd line): final appraisal determination information
-
Rheumatoid arthritis - abatacept (2nd line): final appraisal determination document
-
Rheumatoid arthritis - abatacept (2nd line): final appraisal determination document (PDF 295 KB)
-
Rheumatoid arthritis - abatacept (2nd line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Rheumatoid arthritis - abatacept (2nd line): consultee and commentator comments on the ACD
-
Rheumatoid arthritis - abatacept (2nd line): Bristol-Myers Squibb
-
Rheumatoid arthritis - abatacept (2nd line): Bristol-Myers Squibb (PDF 593 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Arthritis Care
-
Rheumatoid arthritis - abatacept (2nd line): Arthritis Care (PDF 64 KB)
-
Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society
-
Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society (PDF 229 KB)
-
Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology
-
Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology (PDF 165 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing (PDF 61 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathology
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathology (PDF 44 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Department of Health
-
Rheumatoid arthritis - abatacept (2nd line): Department of Health (PDF 80 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Commissioning Support Appraisal Service
-
Rheumatoid arthritis - abatacept (2nd line): Commissioning Support Appraisal Service (PDF 436 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Abbott
-
Rheumatoid arthritis - abatacept (2nd line): Abbott (PDF 86 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Merck Sharpe and Dohme
-
Rheumatoid arthritis - abatacept (2nd line): Merck Sharpe and Dohme (PDF 128 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Pfizer
-
Rheumatoid arthritis - abatacept (2nd line): Pfizer (PDF 306 KB)
-
Rheumatoid arthritis - abatacept (2nd line): comments on the ACD received from the public through the NICE website
-
-
Rheumatoid arthritis - abatacept (2nd line): appraisal consultation
-
Rheumatoid arthritis - abatacept (2nd line): appraisal consultation document information
-
Rheumatoid arthritis - abatacept (2nd line): evaluation report
-
Rheumatoid arthritis - abatacept (2nd line): pre-meeting briefing
-
Rheumatoid arthritis - abatacept (2nd line): pre-meeting briefing (PDF 156 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Evidence Review Group report
-
Rheumatoid arthritis - abatacept (2nd line): Evidence Review Group report
-
Rheumatoid arthritis - abatacept (2nd line): Evidence Review Group report (PDF 1.32 MB)
-
Rheumatoid arthritis - abatacept (2nd line): ERG factual error check
-
Rheumatoid arthritis - abatacept (2nd line): ERG factual error check (PDF 179 KB)
-
Rheumatoid arthritis - abatacept (2nd line): non-manufacturer submissions
-
Rheumatoid arthritis - abatacept (2nd line): British Health Professionals in Rheumatology
-
-
Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology
-
Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology (PDF 61 KB)
-
Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society
-
Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society (PDF 88 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Primary Care Rheumatology Society
-
Rheumatoid arthritis - abatacept (2nd line): Primary Care Rheumatology Society (PDF 55 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing (PDF 66 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathologists
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathologists (PDF 56 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Royal College of Physicians endorsing British Society for Rheumatology
-
-
Rheumatoid arthritis - abatacept (2nd line): manufacturer submission
-
Rheumatoid arthritis - abatacept (2nd line): BMS
-
Rheumatoid arthritis - abatacept (2nd line): BMS (PDF 1.55 MB)
-
Rheumatoid arthritis - abatacept (2nd line): clarification letter to manufacturer from NICE
-
-
Rheumatoid arthritis - abatacept (2nd line): clarification letter response
-
Rheumatoid arthritis - abatacept (2nd line): clarification letter response (PDF 204 KB)
-
Rheumatoid arthritis - abatacept (2nd line): expert written personal statements
-
Rheumatoid arthritis - abatacept (2nd line): Bosworth
-
Rheumatoid arthritis - abatacept (2nd line): expert statement
-
Rheumatoid arthritis - abatacept (2nd line): expert statement (PDF 25 KB)
-
Rheumatoid arthritis - abatacept (2nd line): submission
-
Rheumatoid arthritis - abatacept (2nd line): submission (PDF 102 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Burke
-
Rheumatoid arthritis - abatacept (2nd line): Burke (PDF 48 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Kiely
-
Rheumatoid arthritis - abatacept (2nd line): Kiely (PDF 24 KB)
-
Rheumatoid arthritis - abatacept (2nd line): Taylor
-
Rheumatoid arthritis - abatacept (2nd line): Taylor (PDF 4.04 MB)
-
Rheumatoid arthritis - abatacept (2nd line): final scope
-
Rheumatoid arthritis - abatacept (2nd line): final scope (PDF 63 KB)
-
Rheumatoid arthritis - abatacept (2nd line): final matrix
-
Rheumatoid arthritis - abatacept (2nd line): final matrix (PDF 55 KB)
-
Rheumatoid arthritis - abatacept (2nd line): comments on the draft scope
-
Rheumatoid arthritis - abatacept (2nd line): comments on the draft scope (PDF 128 KB)
-
Rheumatoid arthritis - abatacept (2nd line): comments on the provisional matrix
-
Rheumatoid arthritis - abatacept (2nd line): comments on the provisional matrix (PDF 37 KB)
-
Rheumatoid arthritis - abatacept (2nd line): appendix B draft scope for consultation (pre-referral)
-
-
Rheumatoid arthritis - abatacept (2nd line): appendix C provisional matrix (pre-referral)
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): evaluation report
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final scope
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final scope (PDF 23 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final matrix
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): final matrix (PDF 58 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): manufacturer submission
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): original submission for TA198, tocilizumb for the treatment of rheumatoid arthritis
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): Patient Access Scheme submission from Roche
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): Patient Access Scheme submission addendum from Roche
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): manufacturer comments on the appraisal consultation document from appraisal of TA198, tocilizumab for the treatment of rheumatoid arthritis
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD2
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD2 (PDF 320 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD3
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD3
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD3 (PDF 168 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): letter accompanying updated model
-
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): review report by Decision Support Unit (DSU) (from the appraisal of TA198, tocilizumab for the treatment of rheumatoid arthritis and the rapid review of guidance TA198
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report May 2010
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report May 2010 (PDF 315 KB)
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report September 2011
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report September 2011 (PDF 230 KB)
Rheumatoid arthritis - tocilizumab (rapid review TA198): matrix
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): matrix
-
Rheumatoid arthritis - tocilizumab (rapid review TA198): matrix (PDF 23 KB)